



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study



Chantal B E M Reusken*, Bart L Haagmans*, Marcel A Müller*, Carlos Gutierrez, Gert-Jan Godeke, Benjamin Meyer, Doreen Muth, V Stalin Raj, Laura Smits-De Vries, Victor M Corman, Jan-Felix Drexler, Saskia L Smits, Yasmin E El Tahir, Rita De Sousa, Janko van Beek, Norbert Nowotny, Kees van Maanen, Ezequiel Hidalgo-Hermoso, Berend-Jan Bosch, Peter Rottier, Albert Osterhaus, Christian Gortázar-Schmidt, Christian Drosten, Marion P G Koopmans

Summary

Background A new betacoronavirus—Middle East respiratory syndrome coronavirus (MERS-CoV)—has been identified in patients with severe acute respiratory infection. Although related viruses infect bats, molecular clock analyses have been unable to identify direct ancestors of MERS-CoV. Anecdotal exposure histories suggest that patients had been in contact with dromedary camels or goats. We investigated possible animal reservoirs of MERS-CoV by assessing specific serum antibodies in livestock.

Methods We took sera from animals in the Middle East (Oman) and from elsewhere (Spain, Netherlands, Chile). Cattle (n=80), sheep (n=40), goats (n=40), dromedary camels (n=155), and various other camelid species (n=34) were tested for specific serum IgG by protein microarray using the receptor-binding S1 subunits of spike proteins of MERS-CoV, severe acute respiratory syndrome coronavirus, and human coronavirus OC43. Results were confirmed by virus neutralisation tests for MERS-CoV and bovine coronavirus.

Findings 50 of 50 (100%) sera from Omani camels and 15 of 105 (14%) from Spanish camels had protein-specific antibodies against MERS-CoV spike. Sera from European sheep, goats, cattle, and other camelids had no such antibodies. MERS-CoV neutralising antibody titres varied between 1/320 and 1/2560 for the Omani camel sera and between 1/20 and 1/320 for the Spanish camel sera. There was no evidence for cross-neutralisation by bovine coronavirus antibodies.

Interpretation MERS-CoV or a related virus has infected camel populations. Both titres and seroprevalences in sera from different locations in Oman suggest widespread infection.

Funding European Union, European Centre For Disease Prevention and Control, Deutsche Forschungsgemeinschaft.

Introduction

In 2012, a new betacoronavirus—Middle East respiratory syndrome coronavirus (MERS-CoV)—was identified in patients with severe respiratory disease in the Middle East. As of Aug 2, 2013, 94 laboratory-confirmed cases, including 46 deaths, have been reported to WHO.¹ Illness associated with MERS-CoV infection is characterised primarily by mild-to-severe respiratory complaints, most requiring hospital admission for acute respiratory distress syndrome. Comorbidities and immunosuppression seem to predispose for infection and severe disease,^{2–6} and unpublished serological studies suggest that asymptomatic infections occur.⁷

All cases reported so far have been linked to Jordan, Qatar, Saudi Arabia, and United Arab Emirates. Human-to-human transmission has been reported, particularly in health-care settings, but on the basis of available evidence the basic reproduction number (R_0) is thought to be low, suggesting that the virus is not transmitted readily.^{6,8} Therefore, the primary reservoir of MERS-CoV is probably animals. Different coronaviruses have various hosts including wildlife, livestock, poultry, pets, and

human beings. Coronaviruses can adapt to new host species, as shown by the zoonotic origin of several human coronaviruses.⁹ Human coronavirus OC43 has recent common ancestry with bovine coronaviruses.¹⁰ Rhinolophid bats were identified as a likely reservoir for severe acute respiratory syndrome coronavirus (SARS-CoV), which emerged in people in 2002–03, through intermediate carnivorous hosts.¹¹ Molecular clock analysis¹² showed that bat and civet strains of viruses closely related to SARS-CoV only diverged a few years before the outbreak. Human coronavirus 229E has a common ancestor with coronaviruses found in Ghanaian *Hipposideros* spp bats.¹³

MERS-CoV is able to replicate in various bat cell lines¹⁴ and phylogenetic analyses show that it is closely related to betacoronavirus lineage C viruses from *Pipistrellus* spp bats in Europe and Asia.^{15–18} Molecular clock dating of epidemiologically unlinked isolates of human MERS-CoV estimated their divergence from a common ancestor in mid-2011,^{4,19} with a cluster of isolates from the eastern Arabian peninsula diverging in late 2012.⁴ This finding could suggest that the diversity of

Lancet Infect Dis 2013; 13: 859–66

Published Online
August 9, 2013
[http://dx.doi.org/10.1016/S1473-3099\(13\)70164-6](http://dx.doi.org/10.1016/S1473-3099(13)70164-6)

See [Comment](#) page 827

*Contributed equally

Centre for Infectious Disease Research, Diagnostics and Screening, Division Virology, National Institute for Public Health and the Environment, Bilthoven, Netherlands (C B E M Reusken PhD, G-J Godeke BSc, R De Sousa PhD, J van Beek MSc, Prof M P G Koopmans PhD); Department of Viroscience, Erasmus Medical Centre, Rotterdam, Netherlands (B L Haagmans PhD, V S Raj PhD, S L Smits PhD, Prof A Osterhaus PhD, Prof M P G Koopmans); Institute of Virology, University of Bonn Medical Centre, Bonn, Germany (M A Müller PhD, B Meyer MSc, D Muth PhD, V M Corman MD, J-F Drexler MD, Prof C Drosten MD); Department of Animal Medicine and Surgery, Veterinary Faculty, University of Las Palmas de Gran Canaria, Las Palmas, Canary Islands, Spain (Prof C Gutierrez PhD); Department of Infectious Diseases and Immunology, Utrecht University, Faculty of Veterinary Medicine, Utrecht, Netherlands (L Smits-De Vries MSc, B-J Bosch PhD, Prof P Rottier PhD); Department of Animal and Veterinary Sciences, College of Agricultural and Marine Sciences (Y E El Tahir PhD) and, Department of Microbiology and Immunology, College of Medicine and Health Sciences (Prof N Nowotny PhD), Sultan Qaboos University, Muscat, Oman; The European

Programme for Public Health Microbiology Training, European Center for Disease Control, Stockholm, Sweden (R De Sousa); Viral Zoonoses, Emerging and Vector-Borne Infections Group, Institute of Virology, University of Veterinary Medicine Vienna, Vienna, Austria (Prof N Nowotny); Animal Health Service, Deventer, Netherlands (K van Maanen PhD); Department of Conservation and Research, Parque Zoológico Buin Zoo, Buin, Chile (E Hidalgo-Hermoso DVM); SaBio-IREC (CSIC-UCLM-JCCM), Ciudad Real, Spain (C Gortázar-Schmidt PhD); and Viroclinics Biosciences BV, Rotterdam, Netherlands (S L Smits, Prof A Osterhaus)

Correspondence to: Chantal Reusken, Centre for Infectious Disease Research, Diagnostics and Screening, Division Virology, National Institute for Public Health and the Environment, PO Box 1, 3720BA, Bilthoven, Netherlands Chantal.Reusken@RIVM.nl

MERS-CoV in people is the result of multiple independent, geographically structured, zoonotic events in the Middle East.^{4,19}

Possible animal reservoirs need to be identified to determine how circulation of MERS-CoV is maintained and to break the chain of transmission.²⁰ MERS-CoV can infect cells of several species, including human beings and bats.¹⁴ The functional receptor is conserved between species, suggesting that receptor use is not an important barrier to cross-species transmission.²¹ Data for exposure history of patients are scarce, but suggest contact with livestock, including dromedary camels and goats.^{2,4,5} Food and Agriculture Organization data from 2011 show that cows, goats, sheep, and dromedary camels are the main sources of meat and milk in Jordan, Saudi Arabia, and United Arab Emirates.²²

Serological studies are best suited to screen animal populations, but have not yet been reported for MERS-CoV in animals, although several methods have been described for testing antibodies of people.^{23,24} For specificity, WHO recommends use of a combination of screening assays with recombinant spike protein, and confirmatory testing by neutralisation assays. Here, we describe antibody profiling of serum samples from major livestock species that might be relevant to the epidemiology of MERS-CoV in the Middle East, using samples collected from herds inside and outside the region.

Methods

Serum sample collection

We sampled a cohort of 105 dromedary camels (*Camelus dromedarius*) from two herds on the Canary Islands. 50 were male, 55 were female, 88 were adults, nine were age 3–4 years, seven were age 2 years, and one was age 3 months. Both herds had the same owner, with frequent exchange of animals between the herds. One herd is from a coastal dune habitat with no other livestock, while the other herd is in an inland valley close to a tropical fruit farm, in particular mango and papaya—which could attract fruit bats—and nearby (roughly 500 m) to horse and goat farms with 25 and 300 animals, respectively. The camels were born in the Canary Islands except for three adults, which were imported from Morocco.²⁵ The camels are used in the tourist industry. 80 sera were taken April–June, 2012, nine in May, 2013, and 16 paired sera were taken in these months in 2012, and 2013, all for routine veterinary purposes. Samples were obtained by jugular puncture.

50 female dromedary camels from Oman were sampled in March, 2013. The camels were aged 8–12 years and belonged to different owners from separate locations. The camels are retired racing camels now used for breeding, and blood was taken by jugular puncture for routine screening for brucellosis.




Figure 1: Reactivity of livestock sera with three coronavirus S1 antigens

Fluorescent intensities per antigen at a serum dilution of 1/20. Black lines indicate median. Dashed line is cutoff of the assay. RFU=relative fluorescence units. SARS-CoV=severe acute respiratory syndrome coronavirus. HCoV=human coronavirus. MERS-CoV=Middle East respiratory syndrome coronavirus.




Figure 2: MERS-CoV and human coronavirus OC43 or bovine coronavirus cross-reactivity

Combinations of the mean fluorescent intensities of reactions of sera with MERS-CoV and human coronavirus OC43 antigens from 105 Spanish dromedary camels (A), plaque reduction neutralisation tests for bovine coronavirus and MERS-CoV (B): two representative sera are shown (numbers 15 and 5, corresponding to camel ID numbers in table 2) in dilutions of 1/40, 1/160, and 1/640 as well as the virus input control. All samples were tested in duplicates (only one well shown) and titres were expressed as the serum dilution resulting in a plaque reduction of at least 90%. IgG reactivity of both camel sera to MERS-CoV antigen and human coronavirus OC43 antigen in a two-step dilution series in the microarray (C). IgG reactivity of two two-step serially diluted Omani dromedary camel sera with human coronavirus EMC antigen and human coronavirus OC43 antigen in the microarray (D). RFU=relative fluorescence units. MERS-CoV=Middle East respiratory coronavirus.

Sera were collected for veterinary purposes from two llamas (*Lama glama*), six alpacas (*Vicugna pacos*), and two Bactrian camels (*Camelus bactrianus*) in the Netherlands. Sera were collected for veterinary purposes from two Bactrian camels, 18 alpacas, five llamas, and two guanaco (*Lama guanicoe*) in Buin Zoo in Chile. Sera from cattle (n=40), domestic goats (n=40), and sheep (n=40) were from routine submission to the Dutch Animal Health Service. Sera from Spanish domestic goats (n=40) were provided by the Instituto de Investigación en Recursos Cinegéticos (Ciudad Real, Spain) from submissions for tuberculosis control in 2011. All sera were obtained in agreement with local regulations and Dutch import regulations with regard to animal disease legislation. Positive human control sera for the three antigens used on the microarray were

taken as described previously.²⁴ All samples were stored at -20°C until testing.

Laboratory procedures

We tested the sera for the presence of IgG antibodies reactive with MERS-CoV, SARS-CoV, and human coronavirus OC43 S1 antigens in a protein microarray. The receptor-binding domains, which contain the S1 subunit of spike proteins of MERS-CoV (residues 1–747), SARS-CoV (residues 1–676), and human coronavirus OC43 (residues 1–760) were expressed, purified, and spotted on glass slides. Slides were incubated with serum and species-specific conjugates, as previously described.²⁴ Goat sera were incubated with Alexa Fluor 647-conjugated rabbit anti-goat IgG Fc fragment (Jackson Immuno Research, West Grove, PA, USA);

cow sera with Alexa Fluor 647-conjugated goat anti-bovine IgG (H+L; Jackson Immuno Research); sheep sera with Alexa Fluor 647-conjugated donkey anti-sheep IgG (H+L; Millipore, Temecula, CA, USA); and camelid sera with Dylight 650-conjugated goat anti-llama IgG (H+L; Agrisera, Vännas, Sweden). Fluorescence signals were quantified as described previously.²⁴ We tested the sera for IgG reactivity at a dilution of 1/20 and set an arbitrary cutoff at an average signal intensity of 20 000 relative fluorescence units (RFU). This high cutoff was chosen to reduce cross-reactive false positives.²⁴ We present results as RFU for each set of quadruplicate spots per antigen. Negative fluorescent intensities (caused by background correction) were assigned to 0. Analyses were done with GraphPad Prism (version 6.02).

Sera were heat-inactivated before virus neutralisation by incubation for 30 min at 56°C. Two-fold serial dilutions of sera were prepared using 96-well plates, starting dilution 1/10. MERS-CoV was diluted in Iscove's modified Dulbecco's medium (IMDM) supplemented with clemizole penicillin (penicillin G), streptomycin, and 1% fetal bovine serum, to a dilution of 2000 tissue culture infective dose₅₀ per mL. 50 µL virus suspension was added to the plates and the plates were incubated at 37°C for 1 h. The mixtures of virus

and serum were then incubated on 96-well plates containing Vero cells for 1 h followed by washing with phosphate buffered saline and incubation with IMDM and 1% fetal bovine serum for 3–4 days, after which endpoint titres were measured. All tests were repeated twice independently.

We tested neutralisation activity of sera against MERS-CoV (Erasmus MC isolate) and bovine coronavirus (Nebraska strain) by plaque reduction neutralisation test (90% plaque reduction) with African green monkey kidney cells (cell line Vero B4; DSMZ ACC 33) or bovine kidney cells (cell line PT; CCLV-RIE11) in a 24-well plate format. Virus (30–60 plaque-forming units) and heat-inactivated sera (diluted from 1/40 to 1/640) were pre-incubated in 200 µL of serum-free OPTIpro medium (Life Technologies, Karlsruhe, Germany) at 37°C for 1 h. Virus adsorption was done at 37°C for 1 h. Supernatants were removed and overlaid with Avicel resin (FCM BioPolymer, Brussels, Belgium).⁵ Assays were stopped after 3 days by fixation with 8% paraformaldehyde for 30 min. All samples were tested in duplicate and titres were expressed as the serum dilution resulting in a plaque reduction of at least 90%.

Role of the funding source

The sponsors had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

Sera were tested for IgG antibodies reactive with MERS-CoV, SARS-CoV, and human coronavirus OC43 S1 antigens in a protein microarray (figure 1). Human coronavirus OC43 is serologically closely related to bovine coronavirus,²⁶ diverging at the end of the 19th century.¹⁰ Bovine coronavirus circulates in cows, sheep, goats, and Old and New World camelids.^{27–30} Because bovine coronavirus S1 was not available, human coronavirus OC43 S1 antigen was used as a proxy. Sera from three llamas, four alpacas, one guanaco, and two Bactrian camels reacted with human coronavirus OC43 antigen. One cow and one goat serum reacted with human coronavirus OC43 antigen as did sera from 16 of 105 (15%) Spanish dromedary camels. All sera from cattle, sheep, and goats tested negative for MERS-CoV antigen, but sera from 15 Spanish camels (14%) did react with MERS-CoV antigen (figure 1). The reactivity was highly specific—the same sera did not bind to SARS-CoV antigen but a positive control specimen did. No correlation existed between the reactivity of sera with MERS-CoV antigen and human coronavirus OC43 antigen (figure 2). All but one serum sample that reacted with MERS-CoV antigen were from adult animals. One reactive serum was from a 2-year-old animal.

	Number of serum samples	Positive MERS-CoV neutralisation titre (n; %)	Titre range
Spanish samples (no geographic link)			
MERS-CoV antigen array signal (RFU)			
<10 000	31	0 (0%)	..
10 000–20 000	3	0 (0%)	..
20 000–30 000	3	0 (0%)	..
30 000–40 000	0	0 (0%)	..
>40 000	12	9 (75%)	1/20 to 1/320
Human coronavirus OC43 antigen array signal (RFU)			
<10 000	26	1 (4%)	..
10 000–20 000	8	3 (38%)	..
20 000–30 000	5	2 (40%)	..
30 000–40 000	6	3 (50%)	..
>40 000	4	0 (0%)	..
Omani camel samples (geographic link)			
MERS-CoV antigen array signal (RFU)			
0–40 000	0	0 (0%)	..
>40 000	50	50 (100%)	1/320 to 1/2560
Human coronavirus OC43 antigen array signal (RFU)			
<10 000	3	3 (100%)	..
10 000–20 000	4	4 (100%)	..
20 000–30 000	4	4 (100%)	..
30 000–40 000	5	5 (100%)	..
>40 000	34	34 (100%)	..

RFU=relative fluorescence units. MERS-CoV=Middle East respiratory syndrome coronavirus.

Table 1: Results of neutralising assay for MERS-CoV from Spanish and Omani camel serum samples

To confirm the presence of MERS-CoV specific IgG in the Spanish camel sera, we used a MERS-CoV neutralisation assay to test a subset of 49 camel sera with different degrees of reactivity with MERS-CoV and human coronavirus OC43 antigen according to microarray. Nine Spanish camels had MERS-CoV neutralising antibodies with titres varying between 1/20 and 1/320 (table 1). Three of the 12 sera reacted with MERS-CoV spike antigen but did not neutralise MERS-CoV, most likely because of recognition of non-neutralising epitopes. All MERS-CoV neutralising sera had (almost) saturating reactivity with MERS-CoV antigen on the microarray, whereas reactivity with human coronavirus OC43 antigen varied from negative to 50% of saturating reactivity (table 1). The variable human coronavirus OC43 signals suggest that MERS-CoV did not generally cross-react with human coronavirus OC43 or bovine coronavirus antigens. All nine camels with MERS-CoV neutralising antibodies were born and raised on the Canary Islands; seven were female, two were male. Eight camels were adults, one was 2 years old.

To show that the reactivity of the camel sera with human coronavirus OC43 antigen according to the microarray was caused by the presence of bovine coronavirus IgG and to further exclude MERS-CoV neutralising activity caused by cross-neutralisation by the bovine coronavirus antibodies, we tested camels that had sufficient serum left (n=15) in a comparative MERS-CoV and bovine coronavirus plaque reduction neutralisation test (figure 2, table 2). All camel sera neutralised bovine coronavirus, but with varying titres, suggesting a lower cutoff than 20 000 RFU for OC43 in the microarray (figure 1). Five camels had high neutralising antibody titres against bovine coronavirus (and a mean signal intensity of greater than 50 000 RFU for human coronavirus OC43 antigen on microarray) but were negative for MERS-CoV neutralisation, suggesting that cross-neutralisation in this direction did not occur and that the MERS-CoV neutralising activity was not caused by the presence of bovine coronavirus neutralising antibodies. A serum sample from a patient who had MERS, neutralised MERS-CoV with a high titre (1/640) but neutralised bovine coronavirus less efficiently (titre 1/80). The latter finding was most probably caused by previous infection with human coronavirus OC43—this patient had a high titre (1/>5120) in a human coronavirus OC43 recombinant spike immunofluorescence assay and a saturating signal with human coronavirus OC43 antigen in the microarray. Two human serum samples positive for human coronavirus OC43 did not neutralise MERS-CoV, one of which neutralised bovine coronavirus at a titre of 1/80 (table 2).

We tested 50 sera from dromedary camels in Oman at a dilution of 1/20 by microarray and MERS-CoV neutralisation test. All the sera showed saturating

	PRNT*	PRNT†	Microarray (RFU)	
	MERS-CoV	BCoV	MERS-CoV antigen	HCoV OC43 antigen
Camel				
1	Negative	>1/640	7848	51147
2	Negative	1/320	23235	8164
3	Negative	1/160	1273	20064
4	Negative	>1/640	3725	37972
5	Negative	>1/640	6493	61046
6	Negative	1/160	1321	63015
7	Negative	1/640	62748	62837
8	Negative	1/40	18421	2376
9	1/80	1/160	62775	6554
10	1/40	1/80	59729	9726
11	1/40	1/160	63433	29333
12	1/40	1/640	63377	31207
13	Negative	1/160	13806	5483
14	1/160	1/>640	63438	19775
15	1/160	1/320	63402	12029
Human				
MERS-CoV	1/640	1/80	64353	63437
HCoV-OC43 (13 DPI)	Negative	1/80	2848	>55 000
HCoV-OC43 (10 DPI)	Negative	1/<40	2826	>55 000

PRNT=plaque reduction neutralisation test. MERS-CoV=Middle East respiratory syndrome coronavirus. BCoV=bovine coronavirus. HCoV=human coronavirus. DPI=days post-infection. RFU=relative fluorescence units. *Titration range 1/40 to 1/1280. †Titration range 1/40 to 1/640.

Table 2: Protein microarray and PRNT results from sera from 15 Spanish dromedary camels and three people

reactivity with MERS-CoV antigen on the microarray, no SARS-CoV antigen reactivity, and human coronavirus OC43 antigen reactivity varying between negative (below the cutoff of 20 000 RFU) and saturating signals (figure 1, table 1). Serial dilution of two sera with saturating reactivity for both antigens at the initial dilution of 1/20 showed that MERS-CoV antigen reactivity was still above the cutoff at 1/5120, whereas human coronavirus OC43 antigen reactivity fell below the cutoff at dilutions of 1/80 to 1/320 (figure 2D). Consistent with the microarray data, all sera had high MERS-CoV neutralising capacity, with titres varying between 1/320 (seven of 50 samples) and 1/2560 or more (16 or 50 samples).

Discussion

In this study we describe the presence of MERS-CoV neutralising antibodies in dromedary camels both in a MERS-CoV linked (Oman) and unlinked regions (Canary Islands). All the sera from dromedary camels from Oman and some from Spain had specific IgG reactivity with the MERS-CoV receptor binding domain S1. We confirmed our expectation that another beta-coronavirus—bovine coronavirus—circulated in these camelids.^{29,30} However, all Omani camels and nine

Panel: Research in context**Systematic review**

We searched PubMed for “novel coronavirus EMC” or “MERS-CoV”, we identified 43 reports in English linked to the Middle East respiratory syndrome coronavirus (MERS-CoV) published before July 22, 2013. None of these reports described a serological study for MERS-CoV-specific antibodies in animals.

Interpretation

Our report describes the first MERS-CoV serological study of major livestock relevant to the Middle East. Our study shows that MERS-CoV or a related virus has infected dromedary camel populations. Both titre levels and seroprevalences in sera from different locations in Oman suggest widespread infection of camelids with MERS-CoV or a closely related virus. Targeted studies are needed to confirm our findings and their possible relevance to human cases of MERS-CoV. Comparative seroprevalence testing of historical and more recent samples from camels from different regions for which epidemiological background information is available, as well as virological assessment of samples from seroconverting animals are needed to identify and characterise this MERS-CoV-related virus. In the meantime, we recommend a detailed case history of confirmed MERS-CoV cases, with review of any animal exposures including animal products, and targeted, prospective serosurveys to establish whether camels or their products are a potential source of human infections.

Spanish camels (9%) had specific neutralising antibodies against MERS-CoV that were clearly not caused by cross-neutralisation by bovine coronavirus antibodies.

Our study is the first in which animals have been tested for the presence of antibodies specific to MERS-CoV (panel). Animal screening is necessary to understand the epidemiology of MERS-CoV. At present, bats are thought to be the ultimate reservoirs for several established human coronaviruses as well as SARS-CoV. Accordingly, phylogenetic analysis has shown that MERS-CoV is related to betacoronavirus lineage C viruses found in *Pipistrellus* spp bats.^{15,16} However, direct transmission of MERS-CoV to people from bats seems unlikely.^{4,19} The identification of possible intermediate hosts that are probably in closer contact with people (eg, livestock) is urgently needed. Common livestock species in the Middle East include dromedary camels but also cattle, sheep, and goats. Based on the available data, we cannot rule out circulation of a MERS-related coronavirus in these species—sera were not available from epidemiologically linked regions.

The high prevalence of MERS-CoV neutralising antibodies in dromedary camels from Oman suggests circulation of MERS-CoV or a closely related virus in this

population. However, attempts to identify viral sequences in Spanish camel sera and faecal samples using pancoronavirus and specific betacoronavirus 2C PCR methods^{15,31,32} were unsuccessful (unpublished data), as was untargeted amplification followed by deep sequencing of faecal samples (unpublished data). These results imply that the camels were not actively shedding the virus at the time of sampling.

Less than 10% of the animals in the Canary Islands had MERS-CoV neutralising sera with titres up to 1/320. This low seroprevalence means either that exposure of the animals to other putative reservoirs is rare³³ or that the virus is absent in this closed-off population of roughly 2000 animals.²⁵ We cannot rule out that the population might have once had an outbreak but that by the time of sampling, antibody titres had waned and no new introductions of the virus had occurred. The camels have contact with wild rodents, rabbits, pigeons, and doves and possibly also with bats. Seven insectivorous bat species, including three *Pipistrellus* spp, are native to the Canary Islands, while Egyptian fruit bats (*Rousettus aegyptiacus*) have been introduced.³⁴

The 100% seroprevalence with high titres in Omani camels from different owners and locations suggests a different situation in the Middle East, with widespread circulation of MERS-CoV or a closely related virus. This difference of epidemiology might be because the virus circulating in the Middle East is different to that circulating in Spain, with increased animal transmissibility and human infections.³⁵ In addition, the Omani camels were once racing camels now held for breeding and might be kept in circumstances that favour virus transmission. For cattle, a relation has been established between the incidence and effects of respiratory diseases, management practices, and animal transport.^{36,37}

To our knowledge, the camel populations in Oman and the Canary Islands are not connected. Camels on the Canary Islands were originally imported in the 15th century from the Horn of Africa for labour and transport. Nowadays, import of animals from Africa is banned because of the risk of foot-and-mouth disease. Only three camels in our study were originally imported from Morocco, more than 18 years ago. Because the closest relatives of MERS-CoV were identified very recently in *Neoromicia zuluensis* bats from Africa,³⁸ the introduction of MERS-CoV or related viruses into some African camel populations could have occurred decades ago, giving a possible explanation for MERS-CoV antibodies in camels from the Canary Islands. In the Middle East, huge numbers of camels are imported from Africa to meet the demand for meat. The top five camel breeding countries are all African, and Saudi Arabia and United Arab Emirates are in the top five camel meat producing countries.²² This increased turnover of animals in the Middle East

compared with the Canary Islands could also affect the epidemiology of a virus, through more frequent influx of immunologically naive animals.

Targeted studies are needed to confirm our findings and their possible relevance in relation to the human cases of MERS-CoV. Comparative seroprevalence testing of historical and more recent samples from camels for which epidemiological background information is available, as well as virological assessment of specimens from seroconverting animals are needed to identify and characterise this MERS-CoV-related virus. In the meantime we recommend a detailed case history of people with MERS-CoV, with review of any animal exposures including animal products, and targeted, prospective serosurveys to establish whether camels or their products are a potential source of human infections.

Contributors

CBEMR designed and coordinated the study, wrote the report, searched the published work, analysed and interpreted data, and produced the figures. BLH and MAM wrote the report, produced the figures, and analysed and interpreted data. CG collected samples and wrote the report. G-JG, BM, and DM did laboratory testing and analysed, and interpreted data. VSR, LS-DV, VMC, and PR generated and analysed data. J-FD and B-JB did laboratory testing, analysed data, and wrote the report. SLS did laboratory testing, analysed data, wrote the report, and produced the figures. YEET, KvM, and EH-H collected samples. RDR searched the published work. JvB analysed data and produced the figures. NN collected samples and interpreted data. AO, CD, and MPGK interpreted data and wrote the report. CG-S collected samples, wrote the report, and coordinated the study. MPGK designed the study.

Conflicts of interest

BLH, AO, VSR, and B-JB have a patent pending for a MERS-CoV receptor. The other authors declare that they have no conflicts of interest.

Acknowledgments

We thank Prof MC Horzinek for helpful suggestions. RDS was funded by the European Public Health Training Program (Euphem), ECDC, Stockholm, Sweden. Contributions to the study were funded through the European Union FP7 projects EMPIRE (contract number 223498; to BLH, SLS, AO, CD) and ANTIGONE (contract number 278976; to CG, CD, MPGK, AO). Work in Bonn was also funded by Deutsche Forschungsgemeinschaft (DFG grant DR772/3-1 to CD).

References

- WHO. Global Alert and Response (GAR): novel coronavirus infection http://www.who.int/csr/don/2013_08_01/en/index.html (accessed Aug 1, 2013).
- Albarrak AM, Stephens GM, Hewson R, Memish ZA. Recovery from severe novel coronavirus infection. *Saudi Med J* 2012; **33**: 1265–69.
- Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeh AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. *N Engl J Med* 2013; **368**: 2487–94.
- Drosten C, Seilmaier M, Corman VM, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. *Lancet Infect Dis* 2013; published online June 17. [http://dx.doi.org/10.1016/S1473-3099\(13\)70154-3](http://dx.doi.org/10.1016/S1473-3099(13)70154-3).
- Buchholz U, Müller MA, Nitsche A, et al. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October–November 2012. *Euro Surveill* 2013; **18**: 20406.
- Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. *N Engl J Med* 2013; published online June 19. <http://www.nejm.org/doi/full/10.1056/NEJMoa1306742>.
- WHO. Middle East respiratory syndrome coronavirus (MERS-CoV)–update. http://www.who.int/csr/don/2013_06_22/en/index.html.
- Breban R, Riou J, Fontanet A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. *Lancet* 2013; published online July 5. [http://dx.doi.org/10.1016/S0140-6736\(13\)61492-0](http://dx.doi.org/10.1016/S0140-6736(13)61492-0).
- Woo PC, Lau SK, Huang Y, Yuen KY. Coronavirus diversity, phylogeny and interspecies jumping. *Exp Biol Med* 2009; **234**: 1117–27.
- Vijgen L, Keyaerts E, Lemey P, et al. Evolutionary history of the closely related group 2 coronaviruses: porcine hemagglutinating encephalomyelitis virus, bovine coronavirus, and human coronavirus OC43. *J Virol* 2006; **80**: 7270–74.
- Lau SK, Woo PC, Li KS, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. *Proc Natl Acad Sci USA* 2005; **102**: 14040–45.
- Lau SK, Li KS, Huang Y, et al. Ecoepidemiology and complete genome comparison of different strains of severe acute respiratory syndrome-related *Rhinolophus* bat coronavirus in China reveal bats as a reservoir for acute, self-limiting infection that allows recombination events. *J Virol* 2010; **84**: 2808–19.
- Pfefferle S, Oppong S, Drexler JF, et al. Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana. *Emerg Infect Dis* 2009; **15**: 1377–84.
- Muller MA, Raj VS, Muth D, et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. *mBio* 2012; **3**: e00515–12.
- Annan A, Baldwin HJ, Corman VM, et al. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. *Emerg Infect Dis* 2013; **19**: 456–59.
- Lau SK, Li KS, Tsang AK, et al. Genetic characterization of betacoronavirus lineage C viruses in bats revealed marked sequence divergence in the spike protein of *Pipistrellus* bat coronavirus HKU5 in Japanese pipistrelle: implications on the origin of the novel Middle East respiratory syndrome coronavirus. *J Virol* 2013; **87**: 8638–50.
- Reusken CB, Lina PH, Pielat A, et al. Circulation of group 2 coronaviruses in a bat species common to urban areas in Western Europe. *Vector Borne Zoonotic Dis* 2010; **10**: 785–91.
- Woo PC, Wang M, Lau SK, et al. Comparative analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features. *J Virol* 2007; **81**: 1574–85.
- Cotten M, Lam TT, Watson SJ, et al. Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus. *Emerg Infect Dis* 2013; **19**: 736–42.
- Cauchemez S, Van Kerkhove MD, Riley S, Donnelly CA, Fraser C, Ferguson NM. Transmission scenarios for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and how to tell them apart. *Euro Surveill* 2013; **18**: 20503.
- Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. *Nature* 2013; **495**: 251–54.
- FAOSTAT. 2013. <http://faostat3.fao.org/home/index.html> (accessed June 17, 2013).
- Corman V, Muller M, Costabel U, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. *Euro Surveill* 2012; **17**: 20334.
- Reusken C, Mou H, Godeke G, et al. Specific serology for emerging human coronaviruses by protein microarray. *Euro Surveill* 2013; **18**: 20441.
- Gutierrez C, Juste MC, Corbera JA, Magnus E, Verloo D, Montoya JA. Camel trypanosomiasis in the Canary Islands: assessment of seroprevalence and infection rates using the card agglutination test (CATT/T. evansi) and parasite detection tests. *Vet Parasitol* 2000; **90**: 155–59.
- Gerna G, Cereda PM, Revello MG, Cattaneo E, Battaglia M, Gerna MT. Antigenic and biological relationships between human coronavirus OC43 and neonatal calf diarrhoea coronavirus. *J Gen Virol* 1981; **54**: 91–102.
- Traven M, Carlsson U, Lunden A, Larsson B. Serum antibodies to bovine coronavirus in Swedish sheep. *Acta Veterinaria Scandinavica* 1999; **40**: 69–74.
- Yang DK, Hwang IJ, Kim BH, et al. Serosurveillance of viral diseases in Korean native goats (*Capra hircus*). *J Vet Med Sci* 2008; **70**: 977–79.

- 29 Wunschmann A, Frank R, Pomeroy K, Kapil S. Enteric coronavirus infection in a juvenile dromedary (*Camelus dromedarius*). *J Vet Diagn Invest* 2002; **14**: 441–44.
- 30 Jin L, Cebra CK, Baker RJ, et al. Analysis of the genome sequence of an alpaca coronavirus. *Virology* 2007; **365**: 198–203.
- 31 da Silva Filho LV, Zerbinati RM, Tateno AF, et al. The differential clinical impact of human coronavirus species in children with cystic fibrosis. *J Infect Dis* 2012; **206**: 384–88.
- 32 de Souza Luna LK, Heiser V, Regamey N, et al. Generic detection of coronaviruses and differentiation at the prototype strain level by reverse transcription-PCR and nonfluorescent low-density microarray. *J Clin Microbiol* 2007; **45**: 1049–52.
- 33 Hufnagel L, Brockmann D, Geisel T. Forecast and control of epidemics in a globalized world. *Proc Natl Acad Sci USA* 2004; **101**: 15124–29.
- 34 Trujillo D, Barone R III. La fauna de quiropteros del archipelgo canario. 2006. http://www.magrama.gob.es/es/biodiversidad/temas/conservacion-de-especies-amenazadas/090471228015efe4_tcm7-21160.pdf (accessed July 14, 2013) [in Spanish].
- 35 Woo PC, Huang Y, Lau SK, Yuen KY. Coronavirus genomics and bioinformatics analysis. *Viruses* 2010; **2**: 1804–20.
- 36 Ohlson A, Heuer C, Lockhart C, Traven M, Emanuelson U, Alenius S. Risk factors for seropositivity to bovine coronavirus and bovine respiratory syncytial virus in dairy herds. *Vet Rec* 2010; **167**: 201–06.
- 37 Cernicchiaro N, White BJ, Renter DG, Babcock AH, Kelly L, Slattery R. Associations between the distance traveled from sale barns to commercial feedlots in the United States and overall performance, risk of respiratory disease, and cumulative mortality in feeder cattle during 1997 to 2009. *J Anim Sci* 2012; **90**: 1929–39.
- 38 Ithete NL, Stoffberg S, Corman VM, et al. Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa. *Emerg Infect Dis* 2013. <http://dx.doi.org/10.3201/eid1910.130946>.